WO2012056387A3 - A dermaceutical gel made using sodium fusidate and a process to make it - Google Patents

A dermaceutical gel made using sodium fusidate and a process to make it Download PDF

Info

Publication number
WO2012056387A3
WO2012056387A3 PCT/IB2011/054729 IB2011054729W WO2012056387A3 WO 2012056387 A3 WO2012056387 A3 WO 2012056387A3 IB 2011054729 W IB2011054729 W IB 2011054729W WO 2012056387 A3 WO2012056387 A3 WO 2012056387A3
Authority
WO
WIPO (PCT)
Prior art keywords
gel
sodium fusidate
fusidic acid
dermaceutical
api
Prior art date
Application number
PCT/IB2011/054729
Other languages
French (fr)
Other versions
WO2012056387A2 (en
Inventor
Sulur Subramaniam Vanangamudi
Madhavan Srinivasan
Neelakandan Narayanan Chulliel
Balkrishnana Selvaraj
Sankar Haridas
Original Assignee
Sulur Subramaniam Vanangamudi
Madhavan Srinivasan
Neelakandan Narayanan Chulliel
Balkrishnana Selvaraj
Sankar Haridas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulur Subramaniam Vanangamudi, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Balkrishnana Selvaraj, Sankar Haridas filed Critical Sulur Subramaniam Vanangamudi
Publication of WO2012056387A2 publication Critical patent/WO2012056387A2/en
Publication of WO2012056387A3 publication Critical patent/WO2012056387A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a process to make dermaceutical gel containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment comprising an inert gas, preferably nitrogen. The gel produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The gel also contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, in a gel base; said gel base comprising a natural, semi-synthetic or synthetic polymers, a preservative, an acid, an alkali, a co-solvent, along with water, preferably purified water. The gel produced by the process of the present invention further optionally contains an ingredient selected from a group comprising, an anti oxidant, a chelating agent, and a humectant, or any combination thereof.
PCT/IB2011/054729 2010-10-26 2011-10-24 A dermaceutical gel made using sodium fusidate and a process to make it WO2012056387A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2352/MUM/2010 2010-10-26
IN2352MU2010 2010-10-26

Publications (2)

Publication Number Publication Date
WO2012056387A2 WO2012056387A2 (en) 2012-05-03
WO2012056387A3 true WO2012056387A3 (en) 2012-10-26

Family

ID=45531892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/054729 WO2012056387A2 (en) 2010-10-26 2011-10-24 A dermaceutical gel made using sodium fusidate and a process to make it

Country Status (1)

Country Link
WO (1) WO2012056387A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003966A1 (en) * 1985-01-07 1986-07-17 Leo Pharmaceutical Products Ltd. A/S (Lo^/Vens Kem Ophthalmic gel composition and method of treating eye infections
US6255299B1 (en) * 1985-01-07 2001-07-03 Leo Pharmaceutical Products Ltd. Opthalmic gel composition and method of treating eye infections
WO2008094002A1 (en) * 2007-01-31 2008-08-07 Tds Pharm. Co., Ltd. Hydrogel formulations comprising active drugs for treating wounds
WO2010095090A1 (en) * 2009-02-18 2010-08-26 Sulur Subramaniam Vanangamudi A dermaceutical gel made using sodium fusidate & a process to make it

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003966A1 (en) * 1985-01-07 1986-07-17 Leo Pharmaceutical Products Ltd. A/S (Lo^/Vens Kem Ophthalmic gel composition and method of treating eye infections
US6255299B1 (en) * 1985-01-07 2001-07-03 Leo Pharmaceutical Products Ltd. Opthalmic gel composition and method of treating eye infections
WO2008094002A1 (en) * 2007-01-31 2008-08-07 Tds Pharm. Co., Ltd. Hydrogel formulations comprising active drugs for treating wounds
WO2010095090A1 (en) * 2009-02-18 2010-08-26 Sulur Subramaniam Vanangamudi A dermaceutical gel made using sodium fusidate & a process to make it

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOWEN P: "Particle Size Distribution Measurement from Millimeters to Nanometers and from Rods to Platelets", JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, TAYLOR AND FRANCIS GROUP, NEW YORK, NY, US, vol. 23, no. 5, 1 January 2002 (2002-01-01), pages 631 - 662, XP009102859, ISSN: 0193-2691, DOI: 10.1081/DIS-120015368 *

Also Published As

Publication number Publication date
WO2012056387A2 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
MY166613A (en) Glycerol levulinate ketals and their use
WO2011146155A3 (en) Organo-metallic frameworks derived from carbenophilic metals and method of making same
WO2014097099A3 (en) Glycoconjugation process
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
MX2011012523A (en) Ketal esters of anhydropentitols and uses thereof.
MY170912A (en) Compositions comprising c6 oligosaccharides
WO2011084553A3 (en) Compositions and uses of cis-1,1,1,4,4,4-hexafluoro-2-butene
WO2010146463A3 (en) Composition comprising rebaudioside d for reducing or eliminating aftertaste and preparation method thereof
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2011149711A3 (en) Azeotrope-like composition of hexafluoropropane, hexafluoropropene and hydrogen fluoride
WO2012021715A3 (en) Stable formulations of linaclotide
WO2011130358A3 (en) Compositions and methods for spf enhancement by high concentration cosmetic powder formulations
WO2011056511A3 (en) 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
MX2019012939A (en) Linaclotide-containing formulations for oral administration.
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
WO2010149727A3 (en) Injectable formulations containing asenapine and method of treatment using same
WO2009131604A3 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
WO2010132175A3 (en) Composition incorporating emollient oils into bodywash
WO2012051727A3 (en) Oxidative stable micellar compositions
MX2012012968A (en) Aerosol compositions.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813558

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813558

Country of ref document: EP

Kind code of ref document: A2